Development of an ubiquitin‐proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple‐negative breast cancer

Background Triple‐negative breast cancer (TNBC) is a pathological subtype with a high mortality, and the development of inhibitors in the ubiquitin–proteasome system (UPS) component could be a novel therapeutic tool. Methods Triple‐negative breast cancer data were obtained from The Cancer Genome Atl...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The journal of gene medicine 2024-01, Vol.26 (1), p.e3584-n/a
Hauptverfasser:	Chen, Xiaoqing, Ren, Chongyang, Zhou, Zhisheng, Chen, Jiewen, Fan, Xulong, Li, Xiangzhi, Chen, Jintao, Zhu, Jing
Format:	Artikel
Sprache:	eng
Schlagworte:	chemotherapy sensitivity Cytoplasm Humans Immunotherapy immunotherapy response prognosis Proteasome Endopeptidase Complex - genetics Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - therapy triple‐negative breast cancer Ubiquitins ubiquitin‐proteasome system UPS score
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!